EC Gynaecology

According to GLOBOCAN 2020 estimates, over 314,000 women were diagnosed with ovarian cancer, resulting in 207,000 ovarian cancer-related mortality. Ovarian cancer held the eighth position in global cancer incidence and mortality among women [1]. Notably, transitioned economies, especially in Europe and North America, reported the highest ovarian cancer incidence, whereas African countries consistently exhibited comparatively lower rates [2]. Ovarian cancer is a multifaceted illness comprising various subtypes, each characterized by unique histopathological signatures and varying responses to treatment modalities. In the last five decades, breakthroughs in technologies like microarrays and next-generation sequencing have unveiled molecular alterations defining individual ovarian cancer subtypes. These technologies have also facilitated a more detailed subclassification of the predominant subtype, high-grade serous ovarian cancer [3].

1. Ferlay J., et al. “F. B. global cancer observatory: cancer today. Vol 2021”. Lyon, France: International Agency for Research on Cancer (2021).
2. “CI5Plus: Cancer incidence in five continents time trends”. Lyon, France: International Agency for Research on Cancer (2021).
3. Cook DP and Vanderhyden BC. “Ovarian cancer and the evolution of subtype classifications using transcriptional profiling”. Biology of Reproduction 3 (2019): 645-658.
4. Yang Y., et al. “Tumor microenvironment in ovarian cancer: function and therapeutic strategy”. Frontiers in Cell and Developmental Biology 8 (2020): 758.
5. Hollis RL and Gourley C. “Genetic and molecular changes in ovarian cancer”. Cancer Biology and Medicine 2 (2016): 236-247.
6. Alatise KL., et al. “Mechanisms of drug resistance in ovarian cancer and associated gene targets”. Cancers (Basel)24 (2022): 6246.
7. Pieretti M., et al. “Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival”. Cancer Investigation 1 (2002): 11-23.
8. Kossaï M., et al. “Ovarian cancer: a heterogeneous disease”. Pathobiology1-2 (2018): 41-49.
9. Roberts CM., et al. “The role of intra-tumoral heterogeneity and its clinical relevance in epithelial ovarian cancer recurrence and metastasis”. Cancers (Basel)8 (2019): 1083.
10. Janku F. “Tumor heterogeneity in the clinic: is it a real problem?” Therapeutic Advances in Medical Oncology 2 (2014): 43-51.
11. Guan LY and Lu Y. “New developments in molecular targeted therapy of ovarian cancer”. Discovery Medicine 144 (2018): 219-229.
12. Lum C and Steer CB. “Targeted therapies in the management of ovarian cancer: a focus on older patients”. Drugs and Aging 11 (2017): 821-831.
13. Yang C., et al. “Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant”. Frontiers in Immunology 11 (2020): 577869.
14. Mittica G., et al. “PARP inhibitors in ovarian cancer”. Recent Patents on Anti-Cancer Drug Discovery 4 (2018): 392-410.
15. Gacche RN and Assaraf YG. “Redundant angiogenic signaling and tumor drug resistance”. Drug Resistance Updates 36 (2018): 47-76.
16. Yung MMH., et al. “Orchestrated action of AMPK activation and combined VEGF/PD-1 blockade with lipid metabolic tunning as multi-target therapeutics against ovarian cancers”. International Journal of Molecular Sciences 12 (2022): 6857.
17. Pietilä EA., et al. “Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance”. Nature Communications 1 (2021): 3904.